Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population.
about
Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern ChinaProtein signature of lung cancer tissuesUnlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancerClinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation.Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancerThe revised American Joint Committee on Cancer staging system (7th edition) improves prognostic stratification after minimally invasive esophagectomy for esophagogastric adenocarcinoma.Smoking and lung cancer-induced changes in N-glycosylation of blood serum proteins.Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening.White light, autofluorescence and narrow-band imaging bronchoscopy for diagnosing airway pre-cancerous and early cancer lesions: a systematic review and meta-analysis.Update in lung cancer and mesothelioma 2009.High-content affinity-based proteomics: unlocking protein biomarker discovery.Validation of the 7th TNM classification for non-small cell lung cancer: a retrospective analysis on prognostic implications for operated node-negative cases.Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.
P2860
Q26865990-400043B2-080B-4B0A-9DC1-96B649DC58FDQ28730650-5DC2D1C9-D1C3-4923-ABBB-4E3B05F3C962Q28744369-09384483-E270-4398-9E8B-CF9DAA301D57Q33571227-40B1A07F-F6EA-46D6-89DD-8D75063D1DD8Q34532251-87EC8E99-34A2-4306-9B49-1987AADC2AE4Q36075141-245C95A4-3983-4222-8BF4-79415C908908Q36362594-921D0FF3-0808-4771-BFBA-B2B58ED7BB1CQ36438421-9C550A8E-0628-41B4-B8EF-FC1E3D9088F4Q37528212-46F3407F-E45B-430E-8164-2FD0B801EBCEQ37728779-D9A5E831-488D-461C-A1C5-5979742B50C0Q37809868-7A77EA4D-264F-4DE2-8817-8C5B7A9A9936Q45730663-A02D1E6A-860B-4491-8F73-A99F4DE02063Q45916835-81EC34A3-8A52-4C27-9447-081C69EEFFEAQ51570919-BC36AE23-1020-4EE7-99D0-08F61926600BQ54382849-EB789268-D25D-4A84-9E2B-AC722AEAE30D
P2860
Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Application of the revised lun ...... to a cancer center population.
@en
Application of the revised lung cancer staging system
@nl
type
label
Application of the revised lun ...... to a cancer center population.
@en
Application of the revised lung cancer staging system
@nl
prefLabel
Application of the revised lun ...... to a cancer center population.
@en
Application of the revised lung cancer staging system
@nl
P2093
P2860
P1476
Application of the revised lun ...... to a cancer center population.
@en
P2093
Ara A Vaporciyan
Arlene M Correa
B Nebiyou Bekele
Cesar A Moran
David C Rice
Edmund S Kassis
Garrett L Walsh
Jack A Roth
Jeremy J Erasmus
Katherine M Pisters
P2860
P304
412-418.e1-2
P356
10.1016/J.JTCVS.2009.01.033
P407
P577
2009-05-28T00:00:00Z